Topics

Ofev gains Breakthrough Therapy status for progressive fibrosing ILD

06:35 EDT 11 Oct 2019 | SmartBrief

Boehringer Ingelheim's Ofev, or nintedanib, gained Breakthrough Therapy designation from the FDA as a treatment for patients  -More

Original Article: Ofev gains Breakthrough Therapy status for progressive fibrosing ILD

NEXT ARTICLE

More From BioPortfolio on "Ofev gains Breakthrough Therapy status for progressive fibrosing ILD"

Quick Search

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...